Literature DB >> 18837950

Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors.

Anna V Cherepanova1, Svetlana N Tamkovich, Olga E Bryzgunova, Valentin V Vlassov, Pavel P Laktionov.   

Abstract

The DNase activity and circulating DNA (cirDNA) concentration in blood plasma of healthy donors, patients with chronic prostatitis, and patients with prostate tumors were analyzed. The concentration of the cirDNA from plasma was determined by PicoGreen fluorescent assay. DNase activity in blood was measured using the immunoassay based on the cleavage of a hapten-labeled 974-bp DNA substrate. The mean cirDNA concentration in the plasma of healthy donors was low (21 +/- 4 ng/mL total blood) and was accompanied by high DNase activity (0.17 +/- 0.04 U/mL blood). The mean cirDNA concentration was 90 ng/mL blood (10-234 ng/mL) in the patients with nonmalignant prostate tumors and 115 ng/mL blood (13-339 ng/mL) in those with prostate cancer. The mean DNase activity in blood plasma of the patients with prostate tumors was 0.06 U/mL blood (0-0.12 U/mL). The results obtained demonstrate that increased concentrations of cirDNA in blood of the patients with prostate tumors is accompanied by a decreased DNase activity, confirming our previous data that a low DNase activity in blood plasma of cancer patients is one reason for a high cirDNA concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837950     DOI: 10.1196/annals.1448.016

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro.

Authors:  Janine Aucamp; Abel J Bronkhorst; Dimetrie L Peters; Hayley C Van Dyk; Francois H Van der Westhuizen; Piet J Pretorius
Journal:  Cell Mol Life Sci       Date:  2017-03-18       Impact factor: 9.261

2.  [Circulating cell-free serum DNA: significance as a new biomarker for urological malignancies].

Authors:  J Ellinger; A von Rücker; P J Bastian; S C Müller
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

3.  Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Martina Mazzon; Elisa Paviati; Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Silvia Giudici; Ricciarda Raffaelli; Fabio Ghezzi; Massimo Franchi; Giuseppe Lippi
Journal:  Pathol Oncol Res       Date:  2020-05-27       Impact factor: 3.201

4.  Free circulating DNA and DNase activity in the ejaculates of men with spinal cord injury.

Authors:  Javier Bartolomé-Nebreda; Eduardo Vargas-Baquero; Carmen López-Fernández; José Luís Fernández; Stephen Johnston; Jaime Gosálvez
Journal:  Spinal Cord       Date:  2020-07-10       Impact factor: 2.772

5.  Diverse and widespread contamination evident in the unmapped depths of high throughput sequencing data.

Authors:  Richard W Lusk
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

6.  Tumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia.

Authors:  Rene Cortese; Isaac Almendros; Yang Wang; David Gozal
Journal:  Oncotarget       Date:  2015-01-01

7.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Authors:  Alain R Thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

8.  Complete genes may pass from food to human blood.

Authors:  Sándor Spisák; Norbert Solymosi; Péter Ittzés; András Bodor; Dániel Kondor; Gábor Vattay; Barbara K Barták; Ferenc Sipos; Orsolya Galamb; Zsolt Tulassay; Zoltán Szállási; Simon Rasmussen; Thomas Sicheritz-Ponten; Søren Brunak; Béla Molnár; István Csabai
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

Review 9.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

10.  Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.

Authors:  José A González-Masiá; Damián García-Olmo; Dolores C García-Olmo
Journal:  Onco Targets Ther       Date:  2013-07-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.